Treatment of small-cell lung cancer (SCLC) has long been dominated by chemo(radio)therapy, but the standard of care for first-line extensive-stage SCLC recently changed, following the FDA’s…
Clarivate Epidemiology’s coverage of VTE comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report diagnosed prevalence of obesity/overweight for each…
Clarivate Epidemiology’s coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key venous thromboembolism patient populations covering 171 countries…
Clarivate Epidemiology’s coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of VTE…
Clarivate Epidemiology’s coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of VTE…
Clarivate Epidemiology’s coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of VTE…
Clarivate Epidemiology’s coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of VTE…
Clarivate Epidemiology’s coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of VTE…
Clarivate’s Epidemiology’s coverage of RP comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany,…
Clarivate Epidemiology’s coverage of diabetic nephropathy (DN) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report…
Clarivate Epidemiology’s coverage of diabetic nephropathy (DN) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report…